Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combination nicotine replacement therapy (combination NRT) is a pharmacological strategy for tobacco cessation that involves the simultaneous use of two or more nicotine replacement products. This approach typically pairs a long-acting delivery method, such as a transdermal nicotine patch, with a short-acting form, such as nicotine gum, lozenges, or nasal spray. The transdermal patch provides a steady, baseline level of nicotine to mitigate background withdrawal symptoms, while the short-acting products are used as needed to manage acute cravings or high-risk situations. By addressing both tonic and episodic cravings, combination NRT has been shown to be more effective than single-product NRT monotherapy. The active ingredient is medicinal nicotine, which acts as an agonist at nicotinic acetylcholine receptors (nAChRs) in the brain, mimicking the effects of nicotine from tobacco to reduce withdrawal distress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on combination nicotine replacement therapy (Iowa City VA Health Care System).